← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Vical, Inc.
San Diego, CA
$22,358,424
Total funding
14
Grants
Funding over time
peak $7M · FY2005–09$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$22,358,424 · 14
By mechanism
R44$8,956,537 · 2
U01$5,613,677 · 1
UC1$2,902,252 · 1
R42$1,999,533 · 1
R43$1,196,040 · 4
R01$769,005 · 1
Investigators at Vical, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
Largest grants
Biodefense vaccine for pandemic influenza$2,902,252
UC1 · FY2005 · AI
Pandemic influenza DNA vaccine Development$2,109,388
U01 · FY2008 · AI
Pandemic influenza DNA vaccine Development$2,090,882
U01 · FY2009 · AI
Prophylactic Anthrax Toxin Vaccine$1,950,219
R44 · FY2005 · AI
Prophylactic Anthrax Toxin Vaccine$1,945,441
R44 · FY2004 · AI
Prophylactic Anthrax Toxin Vaccine$1,923,739
R44 · FY2003 · AI
Pandemic influenza DNA vaccine Development$1,413,407
U01 · FY2007 · AI
CMV Immunotherapeutic Vaccine$1,047,535
R44 · FY2007 · AI
CMV Immunotherapeutic Vaccine$1,047,158
R44 · FY2006 · AI
CMV Immunotherapeutic Vaccine$1,042,445
R44 · FY2005 · AI
Herpes Simplex Immunotherapeutic Vaccine$999,845
R42 · FY2009 · AI
Herpes Simplex Immunotherapeutic Vaccine$999,688
R42 · FY2008 · AI
Immune Responses to CMV DNA Vaccination$510,068
R01 · FY2004 · AI
Development of a DNA Vaccine Against Influenza Virus$500,000
R43 · FY2005 · AI
Prophylactic Anthrax Toxin Vaccine$462,918
R41 · FY2002 · AI
HSV Immunotherapeutic Vaccine$299,616
R41 · FY2005 · AI
THERAPEUTIC DNA VACCINES TO TREAT B CELL LYMPHOMA$281,484
R43 · FY2000 · CA
Development of a Cytomegalovirus DNA Vaccine$263,787
R43 · FY2004 · AI
Immune Responses to CMV DNA Vaccination$258,937
R01 · FY2005 · AI
HIV VACCINE PRODUCTION$158,846
N01 · FY2000 · AI